UK microbiome-based drug developer 4D Pharma has become the latest NASDAQ-listed biotech company to go into administration, after a creditor called time on its debts.
4D Pharma Is Latest Biotech Casualty After Creditor Calls Time
Third NASDAQ-Listed Biotech To Cease Trading In 2022
The UK biotech looks to have reached the end of the road, despite some encouraging signs from its microbiome-based pipeline.
More from Business
More from Scrip
Recent moves in the industry include changes at the top at Novo Nordisk and Takeda, plus Nxera Pharma nabs chief commercial officer from AstraZeneca.
• By
China’s imposed large retaliatory tariffs on US pharmaceuticals on 10 April, but some domestic firms with in-licensed, US-origin assets were already moving to localized manufacturing.
• By
The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.